A point-of-care biosensor for rapid detection and differentiation of COVID-19 virus (SARS-CoV-2) and influenza virus using subwavelength grating micro-ring resonator

Shupeng Ning, Hao-Chen Chang, Kang-Chieh Fan, Po-yu Hsiao, Chenghao Feng, Devan Shoemaker, Ray T. Chen

Abstract

In the context of continued spread of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 and the emergence of new variants, the demand for rapid, accurate, and frequent detection is increasing. Besides, the new predominant strain, Omicron variant, manifests more similar clinical features to those of other common respiratory infections. The concurrent detection of multiple potential pathogens helps distinguish SARS-CoV-2 infection from other diseases with overlapping symptoms, which is significant for patients to receive tailored treatment and containing the outbreak. Here, we report a lab-on-a-chip biosensing platform for SARS-CoV-2 detection based on subwavelength grating micro-ring resonator. The sensing surface is functionalized by specific antibody against SARS-CoV-2 spike protein, which could produce redshifts of resonant peaks by antigen-antibody combination, thus achieving quantitative detection. Additionally, the sensor chip is integrated with a microfluidic chip with an anti-backflow Y-shaped structure that enables the concurrent detection of two analytes. In this study, we realized the detection and differentiation of COVID-19 and influenza A H1N1. Experimental results show that the limit of detection of our device reaches 100 fg/mL (1.31 fM) within 15 min detecting time, and cross-reactivity tests manifest the specificity of the optical diagnostic assay. Further, the integrated packaging and streamlined workflow facilitate its use for clinical applications. Thus, the biosensing platform offers a promising solution to achieve ultrasensitive, selective, multiplexed, and quantitative point-of-care detection of COVID-19.

Introduction

The ongoing spread of COVID-19 and the emergence of variants like Omicron have highlighted the need for rapid, accurate diagnostic tools. Because Omicron symptoms often overlap with other respiratory infections like influenza, distinguishing between these pathogens is critical for appropriate clinical management. While RT-PCR is the gold standard, its reliance on centralized labs and long turnaround times limits its utility for point-of-care (POC) testing. This paper presents a "lab-on-a-chip" platform capable of simultaneous, quantitative detection of SARS-CoV-2 and Influenza A (H1N1) in under 15 minutes.

Methodology: Subwavelength Grating Micro-ring Resonators

The sensing platform utilizes Subwavelength Grating Micro-ring Resonators (SUMIRR). Unlike standard micro-rings with solid waveguides, SUMIRR employs a waveguide made of periodic silicon pillars. This subwavelength structure enhances the evanescent field, increasing the interaction between light and the surrounding biological sample, which significantly boosts sensitivity.

SEM images of the subwavelength grating micro-ring resonator showing the periodic silicon pillars and ring radius R.

Surface Functionalization and Microfluidics

The silicon surface is functionalized with specific antibodies—anti-SARS-CoV-2 spike protein and anti-Influenza A nucleoprotein—on separate sensing channels. To manage sample delivery without cross-contamination, the researchers developed a double-layer PDMS microfluidic chip featuring an anti-backflow Y-shaped structure. This design allows for a "single-channel" mode for initial antibody coating and a "dual-channel" mode for concurrent detection.

System Integration

The entire sensor chip is integrated into a 3D-printed holder and coupled with a fiber array for optical input/output, creating a robust, portable diagnostic unit.

Exploded view of the integrated biosensing platform, showing the microfluidic layers, sensing chip, and fiber array.

Results and Discussion

The SUMIRR platform demonstrated exceptional performance across several metrics:

  • Sensitivity: The device achieved a limit of detection (LOD) of 100 fg/mL (1.31 fM) for the SARS-CoV-2 spike protein.
  • Speed: Quantitative results are obtained within 15 minutes.
  • Specificity: Cross-reactivity tests confirmed the platform's ability to distinguish between COVID-19 and influenza. Non-matching antigens produced negligible resonant peak shifts (~15 pm) compared to the significant redshifts observed with target antigens.
  • Bulk Sensitivity: The system reached a bulk sensitivity of 437.2 nm/RIU, with a quality factor ($Q \approx 1650$).

Conclusion

This biosensing platform offers a promising solution for ultrasensitive, multiplexed, and quantitative POC detection. By combining high-sensitivity subwavelength gratings with smart microfluidic design, the system provides a rapid alternative to laboratory-based testing. Future work will focus on validating the device with complex clinical samples like saliva and nasal swabs to ensure performance in real-world diagnostic environments.

Summary updated

Abstract

In the context of continued spread of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 and the emergence of new variants, the demand for rapid, accurate, and frequent detection is increasing. Moreover, the new predominant strain, Omicron variant, manifests more similar clinical features to those of other common respiratory infections. The concurrent detection of multiple potential pathogens helps distinguish SARS-CoV-2 infection from other diseases with overlapping symptoms, which is significant for providing tailored treatment to patients and containing the outbreak. Here, we report a lab-on-a-chip biosensing platform for SARS-CoV-2 detection based on the subwavelength grating micro-ring resonator. The sensing surface is functionalized by specific antibody against SARS-CoV-2 spike protein, which could produce redshifts of resonant peaks by antigen-antibody combination, thus achieving quantitative detection. Additionally, the sensor chip is integrated with a microfluidic chip featuring an anti-backflow Y-shaped structure that enables the concurrent detection of two analytes. In this study, we realized the detection and differentiation of COVID-19 and influenza A H1N1. Experimental results indicate that the limit of detection of our device reaches 100 fg/ml (1.31 fM) within 15 min detecting time, and cross-reactivity tests manifest the specificity of the optical diagnostic assay. Furthermore, the integrated packaging and streamlined workflow facilitate its use for clinical applications. Thus, the biosensing platform presents a promising approach for attaining highly sensitive, selective, multiplexed, and quantitative point-of-care diagnosis and distinction between COVID-19 and influenza.
BibTeX
@article{ning2023point,
  author = {Shupeng Ning and Hao-Chen Chang and Kang-Chieh Fan and Po-yu Hsiao and Chenghao Feng and Devan Shoemaker and Ray T. Chen},
  title = {{A point-of-care biosensor for rapid detection and differentiation of COVID-19 virus (SARS-CoV-2) and influenza virus using subwavelength grating micro-ring resonator}},
  journal = {Applied Physics Reviews},
  year = {2023},
  doi = {10.1063/5.0146079},
}
Figure